이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

IGC-AD1 알츠하이머병으로 인한 치매 초조에 대한 임상시험 (CALMA)

2026년 9월 28일 업데이트: IGC Pharma, LLC

알츠하이머병으로 인한 치매 환자의 초조에 대한 IGC-AD1의 안전성 및 효능에 대한 2상, 다기관, 이중 맹검, 무작위, 위약 대조 시험

The purpose of this study is to assess the efficacy of the oral medication IGC-AD1, a THC-based (Delta-9-Tetrahydrocannabinol) formulation administered twice a day on Agitation in patients with mild to severe dementia from Alzheimer's.

연구 개요

상세 설명

CALMA is a multi-center, double-blind, randomized, placebo-controlled clinical trial. The study targets participants aged 60 and older with mild to severe Alzheimer's dementia who have exhibited clinically significant agitation for at least two weeks prior to enrollment. Agitation caused by other conditions or transient symptoms must be ruled out. Eligibility is determined by a baseline Neuropsychiatric Inventory (NPI-12), Agitation subscale score of ≥4 and the International Psychogeriatric Association (IPA) criteria for agitation.

The investigational medication is an oral solution containing two active ingredients: delta-9 tetrahydrocannabinol (THC) and melatonin. The treatment is administered for 42 days, followed by a two-day taper period at the end of the study.

Safety oversight includes daily calls on days 2, 3, and 4, transitioning to calls every third day thereafter. These calls will review study partners logbook entries, changes in concomitant medications, and adverse events.

The primary objective of the study is to evaluate the efficacy of IGC-AD1 on agitation, measured by changes in the Cohen-Mansfield Agitation Inventory (CMAI) scores from baseline to the End of treatment (EOT). The secondary objective is to assess efficacy by examining CMAI score changes from baseline to week two. Additionally, exploratory objectives are outlined in separate documentation.

Blood samples will be collected during the trial for sparse pharmacokinetic (PK) analysis, blood-based CNS biomarker, and genotyping.

연구 유형

중재적

등록 (추정된)

164

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Florida
      • Maitland, Florida, 미국, 32751
        • ClinCloud, LLC
      • Melbourne, Florida, 미국, 32940
        • ClinCloud, LLC
      • Miami, Florida, 미국, 33133
        • Visionary Investigators Network
      • Miami, Florida, 미국, 33137
        • Miami Jewish Health
      • Miami, Florida, 미국, 33125
        • Central Miami Medical Institute
      • Port Charlotte, Florida, 미국, 33952
        • Neurostudies Inc.
      • Tampa, Florida, 미국, 33613
        • University of South Florida Department of Psychiatry and Behavioral Neurosciences
    • Louisiana
      • Metairie, Louisiana, 미국, 70006
        • Tandem Clinical Research GI, LLC
    • Maryland
      • Baltimore, Maryland, 미국, 21237
        • MedStar Franklin Square Medical Center Neurology
      • Clinton, Maryland, 미국, 20735
        • Medstar Southern Maryland Hospital Center
      • Olney, Maryland, 미국, 20832
        • Medstar Montgomery Medical Center
    • Missouri
      • St Louis, Missouri, 미국, 63128
        • Tekton Research LLC
    • New York
      • Amherst, New York, 미국, 02459
        • Dent Neurologic Institute
      • Brooklyn, New York, 미국, 11229
        • Integrative Clinical Trials, LLC
      • Syracuse, New York, 미국, 13210
        • Ichor Research
    • Oklahoma
      • Oklahoma City, Oklahoma, 미국, 73112
        • Lynn Health Science Institute (LHSI)
    • Rhode Island
      • Providence, Rhode Island, 미국, 02906
        • Butler Hospital, Brown University
    • Texas
      • Austin, Texas, 미국, 78757
        • Senior Adults Specialty Research
      • Dallas, Texas, 미국, 75231
        • Kerwin Medical Center
      • Dallas, Texas, 미국, 75231
        • Baylor Scott and White Research Institute
    • Virginia
      • Richmond, Virginia, 미국, 23219
        • Dominion Medical Associates, Inc.
    • British Columbia
      • Victoria, British Columbia, 캐나다, V8R 1J8
        • Island Health Authorities
    • Ontario
      • Hamilton, Ontario, 캐나다, L8M 1W9
        • Hamilton Health Sciences , Mcmaster University
      • Toronto, Ontario, 캐나다, ON M6A 2E1
        • Baycrest Academy for Research and Education , University of Toronto
    • Quebec
      • Montreal, Quebec, 캐나다, H4H 1R3
        • Douglas Hospital Research Center, McGill university
      • Bayamón, 푸에르토 리코, 00961
        • SCB Research Center Corp
      • Rio Piedras, 푸에르토 리코, 00935
        • The Alliance, Medical Sciences Campus University of Puerto Rico
    • Bayamón
      • Bayamón, Bayamón, 푸에르토 리코, 00961
        • Instituto Sanacoop

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

60년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

To be eligible to participate in this study, the participant must meet all the following criteria:

Inclusion Criteria

  1. Participant and/or Caregiver must provide a signed and dated ICF prior to any study procedures.

  2. Must have a Caregiver who is able and willing to comply with all required study procedures.

  3. The Caregiver must be known to the Participant and must be able to use electronic devices such as a cell phone, video conference over a laptop or cell phone, weighing scale, and be able to learn to take blood pressure, among others.

  4. Based on local practice, Participants that cannot consent may have Caregiver's consent provided the Caregiver has among others a) Power of Attorney, b) is a spouse, or c) a sibling or d) a child or e) a close relation. The practice of accepting consent must be consistent with established practice at the site and jurisdiction.

  5. Participants must consent to CYP450 and apolipoprotein E (ApoE) genotyping, and pharmacokinetics.

  6. Diagnosis of AD by NIA-AA criteria

  7. Clinically significant Agitation assessed by:

    1. NPI (Agitation) ≥ 4
    2. The presence of clinically significant, persistent Agitation based on the IPA definition (Appendix C) rather than those with recent onset and occasional symptoms, and
    3. Agitation not attributable to another psychiatric disorder, suboptimal care conditions, other underlining medical condition, or the physiological effects of a substance.
  8. Negative drug screen, except for benzodiazepines if Participant has been using them in stable doses for at least 3 months before screening.

  9. All medications used for behavioral symptoms should be consistent for at least 6 weeks before screening, with allowance for dose changes up to 25%.

  10. Women must be of no childbearing potential (postmenopausal, defined as cessation of menses for at least 12 months, without an alternative medical cause for amenorrhea) or surgically sterile (hysterectomy, bilateral oophorectomy, or bilateral tubal ligation)).

An individual who meets any of the following criteria will be excluded from participation in this study:

Exclusion Criteria

  1. Prior adverse reaction to cannabinoids or to any component of Study Drug (IGC-AD1 and placebo).
  2. Serious or unstable medical illness, including cardiovascular, hepatic, renal, respiratory, endocrine, neurologic, or hematologic disease, which might confound assessment of safety outcomes.
  3. History of seizures, schizophrenia, or bipolar disorder.
  4. Has participated in an investigational drug or device study within 30 days prior to study start.
  5. Urine drug screen positive for drug use, except for benzodiazepines if Participant was using them previously and their dose had remained stable for at least six weeks before screening.
  6. History of Alcohol and Drug use disorder, within one year prior to enrollment.
  7. Hypertension: Participants with a history of uncontrolled hypertension as determined by the PI and Participants with a hypertensive crisis in the six months prior to enrollment.
  8. Falls: Participants with a history of recurrent falls defined as more than two falls in the six-month period prior to enrollment and a history of falls resulting in injuries or associated with a new acute illness, loss of consciousness, fever, or abnormal blood pressure (Fuller et al., 2000).

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 삼루타

무기와 개입

참가자 그룹 / 팔
개입 / 치료
활성 비교기: Active Comparator: IGC-AD1Active

IGC-AD1-Active, oral solution with two APIs (THC and melatonin).

A non-sterile solution for oral administration.

다른 이름들:
  • 활동적인
위약 비교기: Placebo Comparator: IGC-AD1 Placebo

IGC-AD1-Placebo, oral solution similar to Active in color, taste, and texture, with excipients but without APIs.

A non-sterile solution for oral administration similar in color and texture to the Active.

다른 이름들:
  • 위약

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Agitation
기간: Baseline to week six

Change in mean Cohen Mansfield Agitation Inventory (CMAI) score

Baseline to week six

2차 결과 측정

결과 측정
측정값 설명
기간
Acute Agitation
기간: Baseline to week two

Change in mean Cohen Mansfield Agitation Inventory (CMAI) score

Baseline to week two

기타 결과 측정

결과 측정
측정값 설명
기간
Agitation at week four
기간: Baseline to week four

Change in mean Cohen Mansfield Agitation Inventory (CMAI) score

Baseline to week four
Participant overall wellbeing
기간: Baseline to weeks two and six

Change in the Clinical Global Impression Scale (CGI)

Baseline to weeks two and six
Participant executive functions
기간: Baseline to week six

Change in Mini-Mental State Examination (MMSE2) score

Baseline to week six
Depression
기간: Baseline to weeks two, four, and six

Change in mean Cornell Scale for Depression in Dementia (CSDD) score

Baseline to weeks two, four, and six
Neuropsychiatric symptoms
기간: Baseline to weeks two, four, and six

Change in mean Neuropsychiatric Inventory (NPI-12) score

Baseline to weeks two, four, and six
Participant quality of life
기간: Baseline to weeks two, four and six

Change in mean Quality of Life in Alzheimer's Disease (QOL-AD) score

Baseline to weeks two, four and six
Caregiver burden
기간: Baseline to weeks two and six

Change in mean Zarit Burden Interview (ZBI) score

Baseline to weeks two and six
Psychotropic drugs
기간: Baseline to six weeks

Change in type and dosage of psychotropic drugs

Baseline to six weeks
CYP2C9 polymorphisms on agitation
기간: Baseline to weeks two, four and six

Change in mean Cohen Mansfield Agitation Inventory (CMAI) score for each type of metabolizer group (*1/*1, *1/*3, etc.)

Baseline to weeks two, four and six

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2022년 10월 11일

기본 완료 (추정된)

2026년 11월 1일

연구 완료 (추정된)

2026년 11월 1일

연구 등록 날짜

최초 제출

2022년 9월 14일

QC 기준을 충족하는 최초 제출

2022년 9월 14일

처음 게시됨 (실제)

2022년 9월 16일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 30일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 28일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다